TREA

79275265 - BITBIOME

Follow

Information

  • Trademark
  • 79275265
  • Serial Number
    79275265
  • Registration Number
    6291515
  • Filing Date
    July 25, 2019
    5 years ago
  • Registration Date
    March 16, 2021
    4 years ago
  • Transaction Date
    January 19, 2024
    a year ago
  • Status Date
    March 16, 2021
    4 years ago
  • Published for Opposition Date
    December 29, 2020
    4 years ago
  • Location Date
    March 16, 2021
    4 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    FLETCHER, TRACY L
  • Attorney Docket Number
    US-SHUS-025A
    Attorney Name
    Stacey J. Watson
    Law Office Assigned Location Code
    M60
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
BITBIOME
Case File Statements
  • GS0051: Pharmaceutical preparations for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, and biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical biological preparations for medical purposes for the treatment of allergies, alzheimer disease, adrenocortical insufficiency, allotype pneumonia, alveobronchiolitis, angiocholitis, arthritis, asthmatoid bronchitis, asthma, attention deficit hyperactivity disorder, autism, auto-immune diseases and disorders, autoinflammatory disease, bacteremia, bacterial infection, bacterial pneumonia, bacterial septicemia, bacteroides fragilis, bacteroides thetaiotaomicron, bacteroides uniformis, bacteroides vulgatus, beta thalassemia and myelodysplastic syndromes, biliary tract cancer, pneumonia, blood disease, blood disorders, bone growth disorders, bone and joint infections, breast cancer, bronchitis, bronchiectasis, cancer, cardiovascular diseases, central nervous system diseases and disorders, cervical cancer, cholecystitis, chronic congestive heart failure, clostridium perfringens, collagen diseases, colorectal cancer, community-acquired pneumonia, congestive heart failure, constipation, crohn's disease, cystitis, deep suppurative disease, dementia, depression, diabetes, dermatologic diseases, duodenal ulcer, dysentery, edematous states, endocarditis, endocrine diseases and disorders, endometrial cancer, endometriosis, endonephritis, enteritis, enterococcus faecalis, epididymitis, epilepsy, esophageal cancer, dysentery, febrile neutropenic infections, gastrointestinal diseases and disorders, gastric cancer, gastric ulcer, genetic diseases and disorders, gonorrhea, graft-versus-host disease, granulocytopenia, gynecological infections, head and neck cancer, heart disease, hematologic disorders, hepatic cirrhosis, hypertension, hyperlipidemi, hypercholesterolemia, hypognathadenitis, incontinence, inflammation and inflammatory diseases, inflammatory bowel disease, intra-abdominal infections, intrauterine infection, irritable bowel syndrome, kidney diseases and disorders, leukemia, liver disorders and diseases, lower respiratory tract infections, lung cancer, lymphoma, melanoma, meningitis, menopausal, metabolic diseases and disorders, multiple myeloma, multiple sclerosis, muscular dystrophy, musculoskeletal diseases and disorders, myeloproliferative diseases, myelofibrosis, nasosinusitis, neoplastic diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, neuromuscular and non-gonococcal urethritis, nosocomial pneumonia, obesity, obsessive-compulsive disorder, oncological diseases and disorders, ophthalmic diseases, osteoarthritis, otitis media, ovarian cancer, pain, pancreatic cancer, parkinson's disease, peptostreptococcus micros, peritonitis and septicemia, pneumonia, polymicrobic infections, prevention of chest pain, prostate cancer, prostatitis, pseudomonas aeruginosa, pyelocystiti, pyelonephritis, reflux sophagitis, renal dysfunction, rheumatic disorders, respiratory diseases, respiratory tract infections, schizophrenia, scleroderma, seizures, septicemia, sexual disfunction, sickle cell disease, skin disorders and diseases, skin and skin structure infections, solid organ transplant rejection, spasms, staphylococcus aureus, streptococcus anginosus, streptococcus intermadius, streptococcus constellatus, stroke, superficial pyogenic infection, suppurative lung disease, syphilis, transmissible alimentary toxicosis, the prevention of organ rejection by renal transplant patients, tumors, ulcerative colitis, urethritis, urinary tract infections, urogenital tract infection, urothelial cancer, vaso-occulisive crisis, viral diseases and disorders, and zollinger-ellison syndrome; pharmaceutical preparations for human use, namely, analgesics, antibiotics, anti-fungals, anti-infective preparations, anti-virals, anti-parasitics, and cytokine inhibitory drugs; human growth hormones, immunosuppressants, immunotherapies for the treatment of cancer, medicated dermatological preparations, pharmaceutical antibodies for disease testing, diagnosis, and treatment purposes, pharmaceutical preparations that modulate the immune system, pharmaceutical and biological preparations for immunotherapy, including T Cell therapy, sedatives, smoking cessation preparations, tranquillizers, vaccines for human use, and vitamins; and preparations for destroying vermin, fungicides, herbicides
  • PM0001: BIT BIOME
  • CC0000: Color is not claimed as a feature of the mark.
  • GS0441: Medical screening; providing information relating to medical services; genetic testing for medical purposes
  • GS0421: Structural and functional analysis of genomes; research and development in the field of microorganisms and cells for the healthcare, scientific, biochemical, pharmaceutical, medical, agricultural, food, cosmetic, animal health, diagnostic, chemical, bioremediation, sanitation, oral care, and oil industries; pharmaceutical research and development; pharmaceutical product evaluation services; medical research; medical laboratory services; genetic testing for scientific research purposes
Case File Event Statements
  • 1/19/2024 - a year ago
    40 - NEW REPRESENTATIVE AT IB RECEIVED Type: NREP
  • 7/11/2021 - 3 years ago
    39 - FINAL DECISION TRANSACTION PROCESSED BY IB Type: FINO
  • 6/17/2021 - 3 years ago
    38 - FINAL DISPOSITION NOTICE SENT TO IB Type: FICS
  • 6/17/2021 - 3 years ago
    37 - FINAL DISPOSITION PROCESSED Type: FIMP
  • 6/16/2021 - 3 years ago
    36 - FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB Type: FICR
  • 3/16/2021 - 4 years ago
    35 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 1/10/2021 - 4 years ago
    34 - NOTIFICATION PROCESSED BY IB Type: GPNX
  • 12/29/2020 - 4 years ago
    33 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/29/2020 - 4 years ago
    32 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 12/23/2020 - 4 years ago
    31 - NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB Type: OPNS
  • 12/23/2020 - 4 years ago
    30 - NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB Type: OP2R
  • 12/9/2020 - 4 years ago
    29 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/19/2020 - 4 years ago
    28 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/19/2020 - 4 years ago
    27 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 11/12/2020 - 4 years ago
    26 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 11/12/2020 - 4 years ago
    25 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 11/12/2020 - 4 years ago
    24 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 8/28/2020 - 4 years ago
    23 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 8/28/2020 - 4 years ago
    22 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 8/28/2020 - 4 years ago
    21 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 8/24/2020 - 4 years ago
    20 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 8/24/2020 - 4 years ago
    19 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 8/24/2020 - 4 years ago
    18 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 8/21/2020 - 4 years ago
    17 - ASSIGNED TO LIE Type: ALIE
  • 8/4/2020 - 4 years ago
    16 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 7/10/2020 - 4 years ago
    15 - APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Type: CHAN
  • 7/10/2020 - 4 years ago
    14 - TEAS CHANGE OF CORRESPONDENCE RECEIVED Type: TCCA
  • 7/10/2020 - 4 years ago
    13 - TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS Type: ECDR
  • 7/10/2020 - 4 years ago
    12 - ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Type: ARAA
  • 7/10/2020 - 4 years ago
    11 - TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Type: REAP
  • 7/10/2020 - 4 years ago
    10 - TEAS CHANGE OF OWNER ADDRESS RECEIVED Type: COAR
  • 2/28/2020 - 5 years ago
    9 - REFUSAL PROCESSED BY IB Type: RFNT
  • 2/7/2020 - 5 years ago
    8 - NON-FINAL ACTION MAILED - REFUSAL SENT TO IB Type: RFCS
  • 2/7/2020 - 5 years ago
    7 - REFUSAL PROCESSED BY MPU Type: RFRR
  • 1/11/2020 - 5 years ago
    6 - NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW Type: RFCR
  • 1/11/2020 - 5 years ago
    5 - APPLICATION FILING RECEIPT MAILED Type: MAFR
  • 1/10/2020 - 5 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 1/7/2020 - 5 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/7/2020 - 5 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 12/26/2019 - 5 years ago
    1 - SN ASSIGNED FOR SECT 66A APPL FROM IB Type: REPR